"Suramin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A polyanionic compound with an unknown mechanism of action. It is used parenterally in the treatment of African trypanosomiasis and it has been used clinically with diethylcarbamazine to kill the adult Onchocerca. (From AMA Drug Evaluations Annual, 1992, p1643) It has also been shown to have potent antineoplastic properties.
| Descriptor ID |
D013498
|
| MeSH Number(s) |
D02.455.426.559.847.638.555.750 D02.886.645.600.080.050.650.750 D04.615.638.555.750
|
| Concept/Terms |
Suramin Sodium- Suramin Sodium
- Sodium, Suramin
- Suramin, Hexasodium Salt
- Hexasodium Salt Suramin
- Salt Suramin, Hexasodium
|
Below are MeSH descriptors whose meaning is more general than "Suramin".
Below are MeSH descriptors whose meaning is more specific than "Suramin".
This graph shows the total number of publications written about "Suramin" by people in this website by year, and whether "Suramin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2005 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Suramin" by people in Profiles.
-
Quantitative contributions of processes by which polyanion drugs reduce intracellular bioavailability and transfection efficiency of cationic siRNA lipoplex. J Control Release. 2018 01 28; 270:101-113.
-
Pharmacodynamics of telomerase inhibition and telomere shortening by noncytotoxic suramin. AAPS J. 2015 Jan; 17(1):268-76.
-
Postoperative adjuvant combination therapy with doxorubicin and noncytotoxic suramin in dogs with appendicular osteosarcoma. J Am Anim Hosp Assoc. 2014 Jan-Feb; 50(1):12-8.
-
Phase I/II trial of non-cytotoxic suramin in combination with weekly paclitaxel in metastatic breast cancer treated with prior taxanes. Cancer Chemother Pharmacol. 2012 Jul; 70(1):49-56.
-
Bladder tissue pharmacokinetics of intravesical mitomycin C and suramin in dogs. AAPS J. 2010 Dec; 12(4):586-91.
-
Phase I trial of non-cytotoxic suramin as a modulator of docetaxel and gemcitabine therapy in previously treated patients with non-small cell lung cancer. Cancer Chemother Pharmacol. 2010 Nov; 66(6):1019-29.
-
Noncytotoxic suramin as a chemosensitizer in patients with advanced non-small-cell lung cancer: a phase II study. Ann Oncol. 2008 Nov; 19(11):1903-9.
-
Phase I evaluation of low-dose suramin as chemosensitizer of doxorubicin in dogs with naturally occurring cancers. J Vet Intern Med. 2006 Sep-Oct; 20(5):1172-7.
-
Nontoxic suramin as a chemosensitizer in patients: dosing nomogram development. Pharm Res. 2006 Jun; 23(6):1265-74.
-
Nontoxic suramin treatments enhance docetaxel activity in chemotherapy-pretreated non-small cell lung xenograft tumors. Pharm Res. 2005 Jul; 22(7):1069-78.